Janux Therapeutics (JANX) Accumulated Depreciation (2020 - 2026)

Janux Therapeutics (JANX) has reported Accumulated Depreciation for 7 consecutive years, with $7.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 34.38% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $7.4 million (up 34.38% YoY), while the FY2025 annual figure was $7.0 million, up 40.69% from the prior year.
• Accumulated Depreciation grew to $7.4 million in Q1 2026 per JANX's latest filing, from $7.0 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $7.4 million in Q1 2026 and bottomed at $212000.0 in Q1 2022.
• Historically, Accumulated Depreciation has averaged $3.5 million across 5 years, with a median of $3.4 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation soared 759.09% — and 2026, when it jumped 34.38%.
• Janux Therapeutics' Accumulated Depreciation stood at $972000.0 in 2022, then surged by 199.79% to $2.9 million in 2023, then jumped by 69.94% to $5.0 million in 2024, then jumped by 40.69% to $7.0 million in 2025, then rose by 5.53% to $7.4 million in 2026.
• Business Quant data shows JANX's Accumulated Depreciation at $7.4 million in Q1 2026, $7.0 million in Q4 2025, and $6.5 million in Q3 2025.